Andrew Kruegel

Co-Founder and Head of Chemistry @ Gilgamesh Pharmaceuticals

752y12.xjf046x@z18z85xy3f7b2j269qj1551.220 Sign up to see email

Known information

Medicinal chemist with over 10 years of experience synthesizing and patenting psychedelic and ibogaine analogs
Discovered the mechanism of action of the antidepressant Tianeptine
Founder and Chief Scientific Officer of Kures Therapeutics, which was acquired by ATAI Life Sciences
Holds a PhD in Chemistry

About Gilgamesh Pharmaceuticals

Gilgamesh Pharmaceuticals is a clinical-stage biotechnology company based in New York, focusing on developing innovative therapies for mental health conditions using a unique AI-powered platform.

Report inaccurate information

People similar to Andrew Kruegel

Jonathan Sporn

Founder, CEO @ Gilgamesh Pharmaceuticals

Gerard Marek is the CMO with over 25 years of experience in early clinical development and discovery, having held notable positions at Yale University, Pfizer, Eli Lilly and Company, and Astellas Pharma.

Laszlo Kiss

CBO and Head of Research @ Gilgamesh Pharmaceuticals